Supplementary Figure 3B shows that ROS1+ NSCLC patients presented lower rates of extrathoracic metastases, being the central nervous system (CNS) and liver the most common sites. Contrarily, ALK+ and RET+ NSCLC patients were diagnosed with bone and soft tissue metastatic lesions as well as CNS and liver. Thus, higher NOTCH1 expression in RET+ specimens might be related to the EMT-promoting effect and enhanced metastatic disease in RET+ NSCLC patients. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.